WallStreetZenWallStreetZen

NASDAQ: TRDA
Entrada Therapeutics Inc Stock Ownership - Who owns Entrada Therapeutics?

OverviewForecastEarningsRevenueDividendOwnership

Insider buying vs selling

Have Entrada Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Bernhardt G. ZeiherDirector2026-05-205,000$5.86
$29.32kBuy
Nathan J. DowdenPresident COO2026-05-0415,000$1.74
$26.10kBuy
Natarajan SethuramanPresident Research Develop.2026-05-0425,907$15.39
$398.81kSell
Nathan J. DowdenPresident COO2026-05-0415,000$15.33
$229.95kSell
Kory James WentworthChief Financial Officer2026-04-012,500$12.95
$32.38kSell
Nathan J. DowdenPresident COO2026-03-1011,894$13.05
$155.19kSell
Kory James WentworthChief Financial Officer2026-03-1011,388$13.02
$148.21kSell
Kory James WentworthChief Financial Officer2026-03-095,089$13.00
$66.16kSell
Nathan J. DowdenPresident COO2026-03-093,116$13.02
$40.58kSell
Kory James WentworthChief Financial Officer2026-03-047,988$12.26
$97.89kSell

1 of 6

TRDA insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when TRDA insiders and whales buy or sell their stock.

TRDA Shareholders

What type of owners hold Entrada Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Kush Parmar13.37%5,188,736$32.74MInsider
5am Ventures V LP13.37%5,188,736$32.74MInsider
Baker Bros Advisors LP13.07%5,072,730$32.01MInstitution
Baker Bros Advisors LP12.08%4,691,392$29.60MInsider
Todd Foley11.40%4,425,784$27.93MInsider
Mpm Bioventures 2014 LP11.29%4,381,062$27.64MInsider
Mpm Bioventures 2018 LP11.29%4,381,062$27.64MInsider
5am Venture Management LLC10.45%4,056,379$25.60MInstitution
Roche Holding Ltd7.25%2,813,525$17.75MInsider
Blackrock Inc6.08%2,358,793$14.88MInstitution

1 of 3

TRDA vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
TRDA42.64%57.36%Net SellingNet Selling
FATE51.85%48.15%Net BuyingNet Buying
ALEC65.08%34.92%Net SellingNet Selling
OBIO36.70%63.30%Net BuyingNet Selling
FHTX75.69%14.46%
View Top Biotech Stocks

Entrada Therapeutics Stock Ownership FAQ

Who owns Entrada Therapeutics?

Entrada Therapeutics (NASDAQ: TRDA) is owned by 65.63% institutional shareholders, 88.28% Entrada Therapeutics insiders, and 0.00% retail investors. Kush Parmar is the largest individual Entrada Therapeutics shareholder, owning 5.19M shares representing 13.37% of the company. Kush Parmar's Entrada Therapeutics shares are currently valued at $32.74M.

If you're new to stock investing, here's how to buy Entrada Therapeutics stock.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.